Duloxetine Hcl Capsule, Delayed Release
Product Images NDC 80425-0012

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Duloxetine Hcl (NDC 80425-0012). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advanced Rx Of Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Duloxetine HCl Dr 30m Cap #30 (Duloxetine HCl Dr 30mg Cap Qty 30 Ndc80425 0012)

Duloxetine HCL DR 30 mg delayed release capsules, bottle label for 30 count by Advanced Rx of Tennessee, LLC. The label includes the product name, strength, dosage form, NDC 80425-0012, lot number 30MLX15923, expiration date 10/26/2021, storage instructions, a barcode, and the labeler's logo and address in Nashville, TN.*

FDA Label Image

Duloxetine HCl Dr 30m Cap #60 (Duloxetine HCl Dr 30mg Cap Qty 60 Ndc 80425 0012)

Label for Duloxetine HCL DR 30 mg delayed release capsules by Advanced Rx of Tennessee, LLC. The label indicates a package count of 60 capsules and includes NDC 80425-0012. It shows storage conditions, a lot number, expiration date, and a federal law caution about prescription use.*

FDA Label Image

Structure (Image 0)

Chemical structure diagram of Duloxetine HCL, showing the molecular arrangement including the thiophene ring, naphthalene moiety, and the hydrochloride salt form indicated by NH·HCl.*

FDA Label Image

Figure_1 (Image 1)

A Kaplan-Meier curve chart showing the proportion of patients with relapse over time in days from randomization, comparing two treatments: placebo and duloxetine. The y-axis represents the proportion of patients with relapse, ranging from 0 to 1, and the x-axis shows time in days up to 250. The chart depicts relapse rates increasing over time for both groups, with the placebo group having a higher proportion of relapse than the duloxetine group throughout the observed period.*

FDA Label Image

Figure_2 (Image 2)

A line graph showing the proportion of patients with relapse over time from randomization in days. The graph compares relapse rates between placebo and duloxetine treatment groups, with placebo showing a higher relapse proportion than duloxetine over approximately 280 days.*

FDA Label Image

Figure_3 (Image 3)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. The graph compares four groups: Duloxetine HCL 60mg BD, Duloxetine HCL 60mg QD, Duloxetine HCL 20mg QD, and placebo, showing varying degrees of pain improvement.*

FDA Label Image

Figure_4 (Image 4)

A line graph comparing percent improvement in pain from baseline versus percentage of patients improved. It presents three data series: Duloxetine HCL 60 mg twice daily (BD), Duloxetine HCL 60 mg once daily (QD), and placebo. The graph shows a decline in the percentage of patients improved as the percent improvement in pain increases from 0 to 100.*

FDA Label Image

Figure_5 (Image 5)

A line graph depicting the percentage of patients improved against the percent improvement in pain from baseline. The graph compares three groups: Duloxetine HCL 60 mg twice daily, Duloxetine HCL 60 mg once daily, and placebo. The vertical axis shows the percentage of patients improved, and the horizontal axis shows the percent improvement in pain from baseline.*

FDA Label Image

Figure_6 (Image 6)

A line graph showing the percentage of patients improved according to percent improvement in pain from baseline. The graph compares Duloxetine HCL at doses of 120 mg, 60 mg, and 20 mg once daily against a placebo group. The x-axis represents percent improvement in pain from baseline, and the y-axis represents the percentage of patients improved. Each treatment group is depicted with distinct lines and markers as indicated in the legend.*

FDA Label Image

Figure_8 (Image 7)

A line graph showing the percentage of patients improved plotted against percent improvement in pain from baseline. Two groups are compared: one labeled placebo and the other duloxetine 60/120 mg once daily, with duloxetine showing higher patient improvement percentages across most improvement levels.*

FDA Label Image

Figure_9 (Image 8)

A line graph comparing the percentage of patients improved in pain from baseline between a placebo group and a Duloxetine 60 mg once daily group. The x-axis represents percent improvement in pain from baseline, and the y-axis shows the percentage of patients improved. Two trend lines illustrate patient improvement across increasing pain improvement thresholds.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.